-
-
-
-
-
-
-
RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'
-
-
-
-
-
-
-
Belite Bio files for tinlarebant approval in three new markets
-
-
-
-
-
-
-
BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial
-
-
-
-
-
-
-
FDA accepts BridgeBio's NDA for oral infigratinib for achondroplasia
-
-
-
-
-
-
-
AstraZeneca closes $2 billion equity stake in Summit Therapeutics
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $32 at H.C. Wainwright
-
-
-
-
-
-
-
AstraZeneca invests $2B in Summit Therapeutics preferred shares
-
15,947 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


